Short answer
CATALYST PHARMACEUTICALS, INC. (CPRX) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 3.01 (Notice of Delisting), Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Merger consummation triggered a change in control of Catalyst Pharmaceuticals.
- This filing includes Item 3.01, an item that often signal trouble.
CATALYST PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- Merger consummation triggered a change in control of Catalyst Pharmaceuticals
- Company became a wholly owned subsidiary of Parent
- Existing shareholders’ ownership and governance rights now subject to Parent’s control
- No known arrangements indicating another subsequent change in control
Item 5.02 · Departure/Election of Directors or Officers
- All seven pre-merger directors resigned at the merger’s effective time
- Departures unrelated to disagreements over operations, policies, or practices
- Sergio Marullo di Condojanni, Massimo Marin, and Enrica Dogali became directors of the surviving corporation
- Complete board turnover signals post-merger governance and strategic-control transition
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation and bylaws replaced in full at merger effective time
- Amendments align governance documents with Merger Sub and the surviving corporation
- Exhibit 3.1 contains the amended certificate; Exhibit 3.2 contains amended bylaws
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CATALYST PHARMACEUTICALS, INC. 8-K filings
Get the next CPRX 8-K as it lands
Follow CPRX for push alerts, or ask the research agent what this filing means.